MiMedx Group, Inc (NASDAQ:MDXG) Receives $9.50 Consensus Price Target from Analysts

MiMedx Group, Inc (NASDAQ:MDXG) has received an average rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $9.60.

A number of research firms have weighed in on MDXG. Cantor Fitzgerald decreased their price target on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. Citigroup initiated coverage on shares of MiMedx Group in a research report on Monday. They set a “market outperform” rating on the stock. Lake Street Capital decreased their target price on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 20th. Mizuho lowered their target price on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, December 17th. Finally, Citizens Jmp started coverage on shares of MiMedx Group in a research note on Monday, February 23rd. They issued a “market outperform” rating and a $10.00 price target for the company.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MDXG. CWM LLC lifted its stake in MiMedx Group by 63.8% during the second quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after purchasing an additional 1,892 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of MiMedx Group by 1,808.4% during the 2nd quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock valued at $46,000 after acquiring an additional 7,107 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new stake in shares of MiMedx Group during the 4th quarter valued at $48,000. State of Alaska Department of Revenue bought a new stake in shares of MiMedx Group during the 3rd quarter worth $54,000. Finally, Headlands Technologies LLC acquired a new position in shares of MiMedx Group in the 2nd quarter worth $72,000. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Stock Down 1.0%

Shares of NASDAQ MDXG opened at $4.89 on Monday. The stock has a market capitalization of $724.22 million, a price-to-earnings ratio of 15.28 and a beta of 1.59. MiMedx Group has a 52 week low of $4.78 and a 52 week high of $8.46. The firm has a 50-day moving average price of $5.70 and a 200 day moving average price of $6.58. The company has a quick ratio of 3.95, a current ratio of 4.41 and a debt-to-equity ratio of 0.07.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The company had revenue of $118.10 million during the quarter, compared to analysts’ expectations of $106.78 million. MiMedx Group had a return on equity of 30.61% and a net margin of 11.60%. Equities research analysts anticipate that MiMedx Group will post 0.3 EPS for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.